Dr. David Margolis' laboratory has a long history of translational HIV research: investigating basic molecular, virological and immunological phenomenon, and leveraging insights to develop new interventions in HIV disease. While his work has involved many aspects of HIV science and medicine, for the last two decades a central focus has been the study of molecular mechanisms of HIV proviral latency and persistence despite potent antiretroviral therapy (ART).
He has begun to define the role of epigenetic factors in the restriction of HIV expression; this has led to diverse, multidisciplinary collaborations and translational clinical studies resulting in discovery and high-impact work. He is the principal investigator for CARE (Collaboratory of AIDS Researchers for Eradication), an NIH-funded U19 research organization that seeks to develop the tools to bring an HIV cure from the bench to the clinic.